Clinical trials · Pennsylvania
Advanced Solid Tumor clinical trials in Pennsylvania
We’re tracking 136 recruiting advanced solid tumor studies with a site in Pennsylvania — including Early Phase 1, Phase 1, Phase 1/Phase 2 and Phase 2 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
Dallas, PennsylvaniaAges 18 years+ - NCT04855656RecruitingPhase 1
Lunresertib for advanced solid tumors with specific gene changes
This early-phase trial tests lunresertib alone or with other study drugs in people with advanced solid tumors that have certain tumor gene changes. It aims to see whether the treatment is safe and whether it can help shrink or control cancer.
Philadelphia, PennsylvaniaAges 12 years+ - NCT06803680RecruitingPhase 1
Study of BGB-B455 for advanced solid tumors
This trial tests a new drug, BGB-B455, for people with advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a specific marker called CLDN6, especially in ovarian cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07335497RecruitingPhase 1/Phase 2
Experimental drug CR-001 for advanced solid tumors
This trial tests an experimental drug called CR-001 in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if CR-001 can slow or stop tumor growth.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07160725RecruitingPhase 1/Phase 2
Testing a new drug for advanced solid tumors
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05327010RecruitingPhase 2
Testing a new drug combination for advanced solid tumors
This trial is studying whether a new combination of two cancer drugs, ZEN003694 and talazoparib, can help people with advanced solid tumors that have not responded to other treatments. Talazoparib is a type of drug that targets cancer cells with certain DNA repair problems. The study is divided into groups based on specific gene mutations or previous treatment responses.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06462794RecruitingPhase 1
Study of CX-801 for advanced solid tumors
This trial tests a new drug called CX-801 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04939610RecruitingPhase 1/Phase 2
Studying a targeted radiation drug for advanced solid tumors
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06736704RecruitingPhase 1/Phase 2
Study of SNV4818 for advanced solid tumors with PIK3CA mutation
This trial tests a new drug, SNV4818, for people with advanced solid tumors that have a specific change in the PIK3CA gene. It may help when other treatments have stopped working.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06400485RecruitingEarly Phase 1
Testing AMT-676 for advanced solid tumors
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05329103RecruitingPhase 1
Test drug PEEL-224 in advanced solid tumor cancers
This Phase 1 study tests PEEL-224 in people whose solid tumors are advanced and have not responded to standard treatments (or have no approved standard option). It focuses on safety and early signs of whether the drug can help shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
Philadelphia, PennsylvaniaAges 6 months–25 years - NCT06480552RecruitingPhase 1
Testing a new drug for advanced solid tumors
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06241456RecruitingPhase 1
Experimental CAR-T cells targeting HER2 for advanced solid tumors
This trial tests an experimental 'off-the-shelf' CAR-T cell therapy (called FT825/ONO-8250) that targets a protein called HER2 found on some solid tumors. It may be given alone or with other antibodies to help fight advanced cancer that has not responded to standard treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06220864RecruitingPhase 1
Testing SNV1521 for advanced solid tumors
This trial tests a new oral drug called SNV1521 for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and how well it works against different types of cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07205718RecruitingPhase 1/Phase 2
TAK-188 for advanced solid tumors after immunotherapy
This trial tests a new medication called TAK-188 for people with certain advanced solid tumors that have not responded to standard therapies, including checkpoint inhibitors. It aims to see if TAK-188 can help shrink or control the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06130553RecruitingPhase 1/Phase 2
Study of AZD3470 for patients with MTAP-deficient advanced solid tumors
This trial tests an investigational drug called AZD3470, which blocks a protein called PRMT5, in people whose tumors lack a gene called MTAP. The goal is to see if the drug can shrink tumors or slow their growth.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05101070RecruitingPhase 1/Phase 2
Study of an anti-cancer drug alone or with immunotherapy
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06014502RecruitingPhase 1
Study of IMGS-001 for advanced solid tumors that returned after treatment
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06402201RecruitingPhase 1
First human trial of CDR404 for MAGE-A4 positive solid tumors
This trial tests an experimental treatment called CDR404 for people with certain advanced solid tumors. It is designed for those whose tumors have a specific protein (MAGE-A4) and who have already tried other treatments. The goal is to see if the treatment is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06352359RecruitingPhase 1
Study of ONC 841 for advanced solid tumors
This phase 1 study tests an experimental drug called ONC 841 for people with advanced solid tumors that have not responded to other treatments. The trial aims to find a safe dose and see if the drug can shrink tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06795412RecruitingPhase 1/Phase 2
PYX-201 plus pembrolizumab for advanced solid tumors
This trial tests a new drug called PYX-201 combined with an immunotherapy (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink tumors and help people live longer with manageable side effects.
Pittsburgh, PennsylvaniaAges 18 years+
Advanced Solid Tumor trials by city in Pennsylvania
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting advanced solid tumor studies listed above.
- UPMC Hillman Cancer Center · 6 studies
- Thomas Jefferson University Hospital · 5 studies
- University of Pennsylvania · 5 studies
- Fox Chase Cancer Center · 4 studies
- Children's Hospital of Philadelphia
- Clinical Study Site
- John Hopkins Sidney Kimmel Comprehensive Cancer Center
- Mary Crowley Medical Research Center
What taking part in a advanced solid tumor study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Solid Tumor trials in other states
Common questions
- Are there advanced solid tumor clinical trials in Pennsylvania?
- Yes. We're currently tracking 136 recruiting advanced solid tumor studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced solid tumor study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced solid tumor studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.